Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 50090-3205
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-3205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
The text describes a graph showing the proportion of patients who experienced relapse over time after being randomly assigned to either a placebo or Duloxetine delayed-release capsules. The graph has a y-axis ranging from 0 to 10 and an x-axis showing the time from randomization to relapse in days. The graph suggests that patients on the Duloxetine capsules had a lower proportion of relapse over time compared to those on the placebo.*
Figure 2 (Duloxetine 03)
The text describes a graph displaying the proportion of patients experiencing relapse over time after being randomized to either placebo or Duloxeine delayed-release capsules. The x-axis shows time in days and the y-axis shows the proportion of patients with relapse. There are five data points on the graph at 0, 50, 100, 150, and 200 days for both the placebo and Duloxeine groups. The graph suggests that the proportion of patients with relapse is lower in the Duloxeine group compared to the placebo group.*
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
This document contains information about the percentage of patients who improved after taking placebo or DUL 60/120 mg once daily. The percentage values are given, but there isn't enough context to determine what type of improvement was measured. Additionally, there is a graph showing the percent improvement in pain from baseline (BOCF), with values ranging from 0 to 100, but it is not clear what the x or y-axis represents. Therefore, a comprehensive description of the document is not available.*
Figure 9 (Duloxetine 09)
This document appears to be a graph or chart showing the percentage of patients who improved after taking a certain medication. The medication in question is likely called "DUL" and was taken at a dose of 60 mg once per day. The graph also includes a placebo group for comparison. There is a column of numbers labeled "Percent Improvement in Pain from Baseline (BOCF)", which could indicate that the medication is intended to treat pain. However, it is unclear what the numbers in the table mean without additional context or a key.*
Figure 10 (Duloxetine 10)
This document appears to be a graph displaying the percentage of patients who experienced improvement using a placebo and DUL60/120 mg once daily, as well as the percent improvement in pain from baseline. It is not clear what the specific condition being studied is or what the units of measurement are for the percent improvement.*
Label Image (Lbl500903205)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
